Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 9/2016

02.02.2016 | Original Paper

Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups

verfasst von: Lauren Gooden, Lisa R. Metsch, Margaret R. Pereyra, C. Kevin Malotte, Louise F. Haynes, Antoine Douaihy, Jack Chally, Raul N. Mandler, Daniel J. Feaster

Erschienen in: AIDS and Behavior | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

HIV counseling with testing has been part of HIV prevention in the U.S. since the 1980s. Despite the long-standing history of HIV testing with prevention counseling, the CDC released HIV testing recommendations for health care settings contesting benefits of prevention counseling with testing in reducing sexual risk behaviors among HIV-negatives in 2006. Efficacy of brief HIV risk-reduction counseling (RRC) in decreasing sexual risk among subgroups of substance use treatment clients was examined using multi-site RCT data. Interaction tests between RRC and subgroups were performed; multivariable regression evaluated the relationship between RRC (with rapid testing) and sex risk. Subgroups were defined by demographics, risk type and level, attitudes/perceptions, and behavioral history. There was an effect (p < .0028) of counseling on number of sex partners among some subgroups. Certain subgroups may benefit from HIV RRC; this should be examined in studies with larger sample sizes, designed to assess the specific subgroup(s).
Literatur
1.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17 quiz CE1-4.PubMed
2.
Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010;15(50 Suppl 3):S149–55.CrossRef
3.
Boone MR, Cook SH, Wilson P. Substance use and sexual risk behavior in HIV-positive men who have sex with men: an episode-level analysis. AIDS Behav. 2013;17(5):1883–7.CrossRefPubMed
4.
Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S10–6.CrossRefPubMed
5.
Booth RE, Campbell BK, Mikulich-Gilbertson SK, et al. Reducing HIV-related risk behaviors among injection drug users in residential detoxification. AIDS Behav. 2011;15(1):30–44.CrossRefPubMedPubMedCentral
6.
Ross MW, Hwang LY, Zack C, Bull L, Williams ML. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. Int J STD AIDS. 2002;13(11):769–74.CrossRefPubMed
7.
Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8.CrossRefPubMed
8.
Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.CrossRefPubMed
9.
10.
Gostin L. The epidemics of injection drug use and blood-borne disease: a public health perspective. Georgetown University Law Center. Val U L Rev. 1997;31:669–700.
11.
Mathers B, Cook C, Degenhardt L. Improving the data to strengthen the global response to HIV among people who inject drugs. Int J Drug Policy. 2010;21(2):100–2.CrossRefPubMed
12.
13.
Broz D, Wejnert C, Pham HT, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63(6):1–51.PubMed
14.
15.
Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C. Stimulant-induced enhanced sexual desire as a potential contributing factor in HIV transmission. Am J Psychiatry. 2007;164(1):157–60.CrossRefPubMed
16.
Centers for Disease Control and Prevention (CDC). HIV-associated behaviors among injecting-drug users–23 Cities, United States, May 2005-February 2006. MMWR Morb Mortal Wkly Rep. 2009;58(13):329–32.
17.
Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168(2):93–7.PubMedPubMedCentral
18.
Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(4 Suppl 3):iii7–14.PubMedPubMedCentral
19.
Marshall BD, Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S23–6.CrossRefPubMedPubMedCentral
20.
Centers for Disease Control and Prevention (CDC). HIV infection and HIV-associated behaviors among injecting drug users—20 cities, United States, 2009. MMWR Morb Mortal Wkly Rep. 2012;61(8):133–8.
21.
Tross S, Hanner J, Hu MC, Pavlicova M, Campbell A, Nunes EV. Substance use and high risk sexual behaviors among women in psychosocial outpatient and methadone maintenance treatment programs. Am J Drug Alcohol Abuse. 2009;35(5):368–74.CrossRefPubMedPubMedCentral
22.
Calsyn DA, Cousins SJ, Hatch-Maillette MA, et al. Sex under the influence of drugs or alcohol: common for men in substance abuse treatment and associated with high-risk sexual behavior. Am J Addict. 2010;19(2):119–27.CrossRefPubMedPubMedCentral
23.
McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. J Psychoact Drugs. 2012;44(3):237–42.CrossRef
24.
Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral
25.
Schackman BR, Metsch LR, Colfax GN, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1–2):90–7.CrossRefPubMed
26.
27.
28.
Kellam SG, Brown CH, Poduska JM, et al. Effects of a universal classroom behavior management program in first and second grades on young adult behavioral, psychiatric, and social outcomes. Drug Alcohol Depend. 2008;1(95 Suppl 1):S5–28.CrossRef
29.
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572–9.PubMedPubMedCentral
30.
Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120(4 Suppl 1):S10–20.CrossRefPubMed
31.
Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120(4 Suppl 1):S26–31.CrossRefPubMed
32.
Kaplan SH, Billimek J, Sorkin DH, Ngo-Metzger Q, Greenfield S. Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care. 2010;48(6 Suppl):S9–16.CrossRefPubMed
33.
Su X, Meneses K, McNees P, Johnson WO. Interaction trees: exploring the differential effects of an intervention programme for breast cancer survivors. J R Stat Soc C-App. 2011;60:457–74.CrossRef
34.
Metcalf CA, Douglas JM Jr, Malotte CK, et al. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130–8.CrossRefPubMed
35.
Koblin B, Chesney M, Coates T, EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364(9428):41–50.CrossRefPubMed
36.
Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20(5):731–9.CrossRefPubMed
37.
Clark LR, Brasseux C, Richmond D, Getson P, D’Angelo LJ. Effect of HIV counseling and testing on sexually transmitted diseases and condom use in an urban adolescent population. Arch Pediatr Adolesc Med. 1998;152(3):269–73.CrossRefPubMed
38.
Bolu OO, Lindsey C, Kamb ML, et al. Is HIV/sexually transmitted disease prevention counseling effective among vulnerable populations?: a subset analysis of data collected for a randomized, controlled trial evaluating counseling efficacy (Project RESPECT). Sex Transm Dis. 2004;31(8):469–74.CrossRefPubMed
39.
Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280(13):1161–7.CrossRefPubMed
40.
Song YS, Calsyn DA, Doyle SR, Dierst-Davies R, Chen T, Sorensen JL. Predictors of condom use among men enrolled in drug treatment programs. AIDS Educ Prev. 2009;21(5):460–73.CrossRefPubMedPubMedCentral
41.
Centers for Disease Control and Prevention (CDC). Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence—24 cities, United States, 2006-2007. MMWR Morb Mortal Wkly Rep. 2011;60(31):1045–9.
42.
Brown-Peterside P, Redding CA, Ren L, Koblin BA. Acceptability of a stage-matched expert system intervention to increase condom use among women at high risk of HIV infection in New York City. AIDS Educ Prev. 2000;12(2):171–81.PubMed
43.
Catania JA, Kegeles SM, Coates TJ. Towards an understanding of risk behavior: an AIDS risk reduction model (ARRM). Health Educ Q. Spring. 1990;17(1):53–72.CrossRef
44.
Becker MH. AIDS and behavior change. Public Health Rev. 1998;16:1–11.
45.
Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health. 1991;39(5):219–25.CrossRefPubMed
46.
Brien TM, Thombs DL, Mahoney CA, Wallnau L. Dimensions of self-efficacy among three distinct groups of condom users. J Am Coll Health. 1994;42(4):167–74.CrossRefPubMed
47.
DeHart DD, Birkimer JC. Trying to practice safer sex: development of the sexual risks scale. J Sex Res. 1997;34(1):11–25.CrossRef
48.
Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat. 2007;32(2):189–98.CrossRefPubMed
49.
Rietmeijer CA. Risk reduction counselling for prevention of sexually transmitted infections: how it works and how to make it work. Sex Transm Infect. 2007;83(1):2–9.CrossRefPubMed
50.
Dilley JW, Woods WJ, Sabatino J, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. J Acquir Immune Defic Syndr. 2002;30(2):177–86.CrossRefPubMed
51.
Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55(Suppl 1):S56–62.CrossRefPubMed
52.
Wohl DA, Rosen D, Kaplan AH. HIV and incarceration: dual epidemics. AIDS Read. 2006;16(5):247–.
53.
Corneil TA, Kuyper LM, Shoveller J, et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place. 2006;12(1):79–85.CrossRefPubMed
54.
Surratt HL, Inciardi JA. HIV risk, seropositivity and predictors of infection among homeless and non-homeless women sex workers in Miami, Florida. USA. AIDS Care. 2004;16(5):594–604.CrossRefPubMed
55.
Aidala AA, Lee G, Garbers S, Chiasson MA. Sexual behaviors and sexual risk in a prospective cohort of HIV-positive men and women in New York City, 1994-2002: implications for prevention. AIDS Educ Prev. 2006;18(1):12–32.CrossRefPubMed
56.
Dickson-Gomez J, Hilario H, Convey M, Corbett AM, Weeks M, Martinez M. The relationship between housing status and HIV risk among active drug users: a qualitative analysis. Subst Use Misuse. 2009;44(2):139–62.CrossRefPubMedPubMedCentral
57.
58.
Ng BE, Butler LM, Horvath T, Rutherford GW. Population-based biomedical sexually transmitted infection control interventions for reducing HIV infection. Cochrane Database Syst Rev. 2011;16(3):1220.
59.
Stein JA, Nyamathi A, Ullman JB, Bentler PM. Impact of marriage on HIV/AIDS risk behaviors among impoverished, at-risk couples: a multilevel latent variable approach. AIDS Behav. 2007;11(1):87–98.CrossRefPubMed
60.
Finer LB, Darroch JE, Singh S. Sexual partnership patterns as a behavioral risk factor for sexually transmitted diseases. Fam Plann Perspect. 1999;31(5):228–36.CrossRefPubMed
61.
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.CrossRefPubMed
62.
Mizuno Y, Purcell DW, Mackenzie S, et al. Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE). J Acquir Immune Defic Syndr. 2007;1(46 Suppl 2):S48–54.CrossRef
63.
Zimmerman RS, Langer LM. Improving estimates of prevalence rates of sensitive behaviors: the randomized lists technique and consideration of self-reported honesty. J Sex Res. 1995;32:107–17.CrossRef
64.
Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the aware randomized clinical trial. JAMA. 2013;310(16):1701–10.CrossRefPubMedPubMedCentral
65.
Peterman TA, Lin LS, Newman DR, et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT study Group. Sex Transm Dis. 2000;27(8):446–51.CrossRefPubMed
66.
Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am J Public Health. 1999;89(9):1397–405.CrossRefPubMedPubMedCentral
67.
Centers for Disease Control and Prevention (CDC). Recommendations for HIV testing services and outpatients in acute-care hospital settings; and Technical guidance on HIV counseling. MMWR Recomm Rep. 1993;42(2):5–9.
68.
Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064–9.CrossRefPubMed
69.
Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey SG. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56.CrossRefPubMed
70.
Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57(3):229–36.CrossRefPubMed
71.
Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat. 2002;12(3):347–58.CrossRefPubMed
72.
Lagakos SW. The challenge of subgroup analyses–reporting without distorting. N Engl J Med. 2006;354(16):1667–9.CrossRefPubMed
73.
Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48(1):23–40.CrossRefPubMed
74.
Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917–30.CrossRefPubMed
75.
Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176–86.CrossRefPubMed
76.
Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266(1):93–8.CrossRefPubMed
77.
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine–reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189–94.CrossRefPubMed
78.
79.
Foster JC, Taylor JM, Ruberg SJ. Subgroup identification from randomized clinical trial data. Stat Med. 2011;30(24):2867–80.CrossRefPubMed
Metadaten
Titel
Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups
verfasst von
Lauren Gooden
Lisa R. Metsch
Margaret R. Pereyra
C. Kevin Malotte
Louise F. Haynes
Antoine Douaihy
Jack Chally
Raul N. Mandler
Daniel J. Feaster
Publikationsdatum
02.02.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 9/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1300-6

Weitere Artikel der Ausgabe 9/2016

AIDS and Behavior 9/2016 Zur Ausgabe

Original Paper

Mixed-Methods Evaluation of a Novel, Structured, Community-Based Support and Education Intervention for Individuals with HIV/AIDS in KwaZulu-Natal, South Africa

Original Paper

Work It Out Together: Preliminary Efficacy of a Parent and Adolescent DVD and Workbook Intervention on Adolescent Sexual and Substance Use Attitudes and Parenting Behaviors

Original Paper

Abriendo Puertas: Feasibility and Effectiveness a Multi-Level Intervention to Improve HIV Outcomes Among Female Sex Workers Living with HIV in the Dominican Republic

Original Paper

Social and Structural Determinants of Cervical Health among Women Engaged in HIV Care

Original Paper

Explanatory Models and Illness Experience of People Living with HIV

Original Paper

Delivering Prevention Interventions to People Living with HIV in Clinical Care Settings: Results of a Cluster Randomized Trial in Kenya, Namibia, and Tanzania

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise